4:38 PM
 | 
Mar 06, 2018
 |  BC Innovations  |  Translation in Brief

Arcing toward AI

British partnership using AI for early drug discovery

LifeArc announced in January it is tapping into AI capabilities at the University of Cambridge’s Milner Therapeutics Institute through a partnership aimed at identifying and validating new targets for cancer immunotherapy and respiratory disease early in the drug discovery process.

Catherine Kettleborough, head of biology and associate director for medical research charity LifeArc, told BioCentury the primary aim of the project is to determine where in the drug development process AI and machine learning technologies can have the greatest impact to improve end-target validation and...

Read the full 405 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Innovations

Article Purchase

$100 USD
More Info >